Beida Pharmaceuticals introduced pD-1 and CTLA-4 projects.

Guide: Beida Pharmaceuticals has signed an Exclusive License Agreement with Agenus to introduce the PD-1 and CTLA-4 projectsJune 20, 2020, the 8th meeting of the 3rd Board of Directors of Beida Pharmaceutical Co., Ltdconsidered and adopted the Bill on the Introduction of PD-1 and CTLA-4 Projects by The CompanyThe Company has partnered with Agenus Incto pay a down payment of $15 million to Agenus in its own funds, and to subscribe for a $20 million cash share of Agenus through Beda Investments (Hong Kong) Co., Ltd., which Beida Pharmaceuticals acquired in China (including Hong Kong and Macau) Exclusive development and commercialization of Balstilimab (PD-1 antibody) and Zalifrelimab (CTLA-4 antibodies) in the exclusive development and commercialization of all oncology and non-oncology indications except bladder administration in the regionBalstilimab and Zalifrelimab are all tumor immunomonoclonal antibodies of Agenus
Balstilimab is an immunocheckpoint inhibitor that targets the full human-derived monoclonal antibodies of the procedural death receptor 1 (PD1) on T cellsZalifrelimab is a cytotoxic T lymphocyte-related antigen 4 (CTLA-4) full-human monoclonal antibody targeted at expression on the surface of T cellsBoth PD-1 and CTLA-4 are popular and already targeted in the direction of tumor immunotherapyUp to now, the market and research and development of PD-1 and CTLA-4 antibodies in China is as follows:PD-1 antibodya total of 6 PD-1 products in China were approved for listing, namely, 100-times Meimei Squibb's Navuliu monotonic, Mershadon's Paboli bead singtag, Junshi bio's Trepri sing-imo, Cinda Bio's Cindy Singli singanti-singanti, Hengrui The approved indications of the medicine's Carilli Zuma and Baiji Shenzhou's Trielli Zuma include classic Hodgkin's lymphoma, melanoma, non-small cell lung cancer, gastric or gastroesophageal connectivity adenocarcinoma, liver cell cancer, head and neck scale cancer and urinary skin cancer2020, there will also be a reputation for the pharmaceutical industry and the drug ming biological co-development of Thesaali sepsis, Kangfang Bio and China Biopharmaceuticalco jointly developed by the Paiamply listed, indications are classic Hodgkin lymphomaCTLA-4 antibodythe domestic market has not yet been APPROVEd for the market OF CTLA-4 productsThe fastest-growing step so far is the Ipitumizumatam injection of Persimmon, which will be listed as a single drug in December 2019 (indications are not disclosed)Next to that progress was iBI-310, a biosimilar drug developed by Cinda Bio, whose Phase III clinical trial for sindi-singli sepsis for postoperative assisted therapy for melanoma was launched in February 2020 In addition to the above two varieties, there are 8 CTLA-4 products in the research products in the declared clinical or clinical Phase I stage currently, Agenus is conducting Phase II clinical trials with Balstilimab and Zalifrelimab, and plans to submit to the FDA in 2020 a listing application for Balstilimab monotherapy, as well as Balstilimab and ifrelimab, which are used in the form of refractive cervical cancer indications .